BACKGROUND: Red blood cell-derived microparticles are biologically active, submicron vesicles shed by erythrocytes during storage. Recent clinical studies have linked the duration of red blood cell storage with thromboembolic events in critically ill transfusion recipients. In the present study, we hypothesized that microparticles from aged packed red blood cell units promote a hypercoagulable state in a murine model of transfusion. METHODS: Microparticles were isolated from aged, murine packed red blood cell units via serial centrifugation. Healthy male C57BL/6 mice were transfused with microparticles or an equivalent volume of vehicle, and whole blood was harvested for analysis via rotational thromboelastometry. Serum was harvested from a separate set of mice after microparticles or saline injection, and analyzed for fibrinogen levels. Red blood cell-derived microparticles were analyzed for their ability to convert prothrombin to thrombin. Finally, mice were transfused with either red blood cell microparticles or saline vehicle, and a tail bleeding time assay was performed after an equilibration period of 2, 6, 12, or 24 hours. RESULTS: Mice injected with red blood cell-derived microparticles demonstrated an accelerated clot formation time (109.3 ± 26.9 vs 141.6 ± 28.2 sec) and increased α angle (68.8 ± 5.0 degrees vs 62.8 ± 4.7 degrees) compared with control (each P < .05). Clotting time and maximum clot firmness were not significantly different between the 2 groups. Red blood cell-derived microparticles exhibited a hundredfold greater conversion of prothrombin substrate to its active thrombin form (66.60 ± 0.03 vs 0.70 ± 0.01 peak OD; P<.0001). Additionally, serum fibrinogen levels were lower in microparticles-injected mice compared with saline vehicle, suggesting thrombin-mediated conversion to insoluble fibrin (14.0 vs 16.5 µg/mL, P<.05). In the tail bleeding time model, there was a more rapid cessation of bleeding at 2 hours posttransfusion (90.6 vs 123.7 sec) and 6 hours posttransfusion (87.1 vs 141.4 sec) in microparticles-injected mice as compared with saline vehicle (each P<.05). There was no difference in tail bleeding time at 12 or 24 hours. CONCLUSION: Red blood cell-derived microparticles induce a transient hypercoagulable state through accelerated activation of clotting factors.
BACKGROUND: Red blood cell-derived microparticles are biologically active, submicron vesicles shed by erythrocytes during storage. Recent clinical studies have linked the duration of red blood cell storage with thromboembolic events in critically ill transfusion recipients. In the present study, we hypothesized that microparticles from aged packed red blood cell units promote a hypercoagulable state in a murine model of transfusion. METHODS: Microparticles were isolated from aged, murine packed red blood cell units via serial centrifugation. Healthy male C57BL/6 mice were transfused with microparticles or an equivalent volume of vehicle, and whole blood was harvested for analysis via rotational thromboelastometry. Serum was harvested from a separate set of mice after microparticles or saline injection, and analyzed for fibrinogen levels. Red blood cell-derived microparticles were analyzed for their ability to convert prothrombin to thrombin. Finally, mice were transfused with either red blood cell microparticles or saline vehicle, and a tail bleeding time assay was performed after an equilibration period of 2, 6, 12, or 24 hours. RESULTS:Mice injected with red blood cell-derived microparticles demonstrated an accelerated clot formation time (109.3 ± 26.9 vs 141.6 ± 28.2 sec) and increased α angle (68.8 ± 5.0 degrees vs 62.8 ± 4.7 degrees) compared with control (each P < .05). Clotting time and maximum clot firmness were not significantly different between the 2 groups. Red blood cell-derived microparticles exhibited a hundredfold greater conversion of prothrombin substrate to its active thrombin form (66.60 ± 0.03 vs 0.70 ± 0.01 peak OD; P<.0001). Additionally, serum fibrinogen levels were lower in microparticles-injected mice compared with saline vehicle, suggesting thrombin-mediated conversion to insoluble fibrin (14.0 vs 16.5 µg/mL, P<.05). In the tail bleeding time model, there was a more rapid cessation of bleeding at 2 hours posttransfusion (90.6 vs 123.7 sec) and 6 hours posttransfusion (87.1 vs 141.4 sec) in microparticles-injected miceas compared with saline vehicle (each P<.05). There was no difference in tail bleeding time at 12 or 24 hours. CONCLUSION: Red blood cell-derived microparticles induce a transient hypercoagulable state through accelerated activation of clotting factors.
Authors: Daryl J Kor; Rahul Kashyap; Richard B Weiskopf; Gregory A Wilson; Camille M van Buskirk; Jeffrey L Winters; Michael Malinchoc; Rolf D Hubmayr; Ognjen Gajic Journal: Am J Respir Crit Care Med Date: 2012-01-26 Impact factor: 21.405
Authors: Richard S Hoehn; Peter L Jernigan; Lukasz Japtok; Alex L Chang; Emily F Midura; Charles C Caldwell; Burkhard Kleuser; Alex B Lentsch; Michael J Edwards; Erich Gulbins; Timothy A Pritts Journal: Ann Surg Date: 2017-01 Impact factor: 12.969
Authors: Marie E Steiner; Paul M Ness; Susan F Assmann; Darrell J Triulzi; Steven R Sloan; Meghan Delaney; Suzanne Granger; Elliott Bennett-Guerrero; Morris A Blajchman; Vincent Scavo; Jeffrey L Carson; Jerrold H Levy; Glenn Whitman; Pamela D'Andrea; Shelley Pulkrabek; Thomas L Ortel; Larissa Bornikova; Thomas Raife; Kathleen E Puca; Richard M Kaufman; Gregory A Nuttall; Pampee P Young; Samuel Youssef; Richard Engelman; Philip E Greilich; Ronald Miles; Cassandra D Josephson; Arthur Bracey; Rhonda Cooke; Jeffrey McCullough; Robert Hunsaker; Lynne Uhl; Janice G McFarland; Yara Park; Melissa M Cushing; Charles T Klodell; Ravindra Karanam; Pamela R Roberts; Cornelius Dyke; Eldad A Hod; Christopher P Stowell Journal: N Engl J Med Date: 2015-04-09 Impact factor: 91.245
Authors: Jeffry L Kashuk; Ernest E Moore; Allison Sabel; Carlton Barnett; James Haenel; Tuan Le; Michael Pezold; Jerry Lawrence; Walter L Biffl; C Clay Cothren; Jeffrey L Johnson Journal: Surgery Date: 2009-10 Impact factor: 3.982
Authors: Dean A Fergusson; Paul Hébert; Debora L Hogan; Louise LeBel; Nicole Rouvinez-Bouali; John A Smyth; Koravangattu Sankaran; Alan Tinmouth; Morris A Blajchman; Lajos Kovacs; Christian Lachance; Shoo Lee; C Robin Walker; Brian Hutton; Robin Ducharme; Katelyn Balchin; Tim Ramsay; Jason C Ford; Ashok Kakadekar; Kuppuchipalayam Ramesh; Stan Shapiro Journal: JAMA Date: 2012-10-10 Impact factor: 56.272
Authors: Kasiemobi E Pulliam; Bernadin Joseph; Rosalie A Veile; Lou Ann Friend; Amy T Makley; Charles C Caldwell; Alex B Lentsch; Michael D Goodman; Timothy A Pritts Journal: J Trauma Acute Care Surg Date: 2020-10 Impact factor: 3.313
Authors: Denis F Noubouossie; Michael W Henderson; Micah Mooberry; Anton Ilich; Patrick Ellsworth; Mark Piegore; Sarah C Skinner; Rafal Pawlinski; Ian Welsby; Thomas Renné; Maureane Hoffman; Dougald M Monroe; Nigel S Key Journal: Blood Date: 2020-03-05 Impact factor: 22.113
Authors: Kasiemobi E Pulliam; Bernadin Joseph; Mackenzie C Morris; Rosalie A Veile; Rebecca M Schuster; Amy T Makley; Timothy A Pritts; Michael D Goodman Journal: Thromb Res Date: 2020-07-01 Impact factor: 3.944
Authors: Young Kim; Michael D Goodman; Andrew D Jung; William A Abplanalp; Rebecca M Schuster; Charles C Caldwell; Alex B Lentsch; Timothy A Pritts Journal: Thromb Res Date: 2019-11-26 Impact factor: 3.944
Authors: Stephan Hasse; Anne-Sophie Julien; Anne-Claire Duchez; Chenqi Zhao; Eric Boilard; Paul R Fortin; Sylvain G Bourgoin Journal: Lupus Sci Med Date: 2022-03